SELLAS Life Sciences (SLS) Non-Current Deferred Tax Liability (2015 - 2021)

SELLAS Life Sciences (SLS) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $152000.0 in Q4 2021.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 89.03% year-over-year to $152000.0 in Q4 2021; TTM through Dec 2021 was $152000.0, a 89.03% decrease from a year earlier, with the FY2021 full-year figure at $152000.0, down 89.03% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2021 stood at $152000.0, down from $239000.0 in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for SLS reached as high as $5.7 million in Q1 2017 and fell as low as $152000.0 in Q4 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $1.5 million across 5 years, with a median of $357000.0 in 2018.
• Across the five-year window, Non-Current Deferred Tax Liability plunged 89.62% in 2018 and soared 428.63% in 2020, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $3.4 million in 2017, then plunged by 89.62% to $357000.0 in 2018, then declined by 26.61% to $262000.0 in 2019, then surged by 428.63% to $1.4 million in 2020, then sank by 89.03% to $152000.0 in 2021.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $152000.0 in Q4 2021, $239000.0 in Q3 2021, and $239000.0 in Q2 2021.